24 Morrison Foerster With this transaction, we anticipate being able to use a new modality that can have a profound impact on patients’ lives. Our hope is to combine the strengths of Kyowa Kirin and Orchard Therapeutics with mutual respect to realize the successful creation and delivery of life-changing value for patients living with rare and life-threatening inherited diseases. TakeyoshiYamashita, Ph.D. Director of the Board, Chief Medical Officer, Senior Managing Executive Officer, Kyowa Kirin
RkJQdWJsaXNoZXIy NTU5OTQ5